Eli Lilly(LLY.US)'s new drug approved in China for key Phase 3 clinical trials

Reuters Finance APP has learned that recently, Eli Lilly (LLY.US) announced that the new long-acting glucagon-like peptide-1 receptor agonist, eloralintide, has been approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). Simultaneously, three global Phase 3 clinical trials are being conducted in China to support future registration of this product for multiple indications, including weight management, to meet the clinical needs of patients with obesity or overweight and their related comorbidities, providing more effective and well-tolerated treatment options.

Eloralintide is a potent, selective, long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist that binds with high affinity to human GLP-1 receptor (AMY1R), while maintaining selectivity for human calcitonin receptor (hCTR). It balances efficacy in weight reduction with gastrointestinal tolerability. Its selectivity for GLP-1 receptors may reduce potential risks associated with calcitonin receptor activity. Due to its long plasma half-life (about 14 days), the product is suitable for once-weekly subcutaneous (SC) administration.

Eloralintide is being developed for the following indications: as an adjunct to diet and exercise for long-term weight management in adults with obesity or overweight (with at least one weight-related comorbidity); and as a combination therapy for adults who have used stable doses of incretin-based medications but have not achieved treatment goals, for long-term weight management.